Autologous Bone Marrow Transplantation - Blog Science Connections

458 High-Dose Chemotherapy and ABMT in Breast Cancer
Table 2. Response and Progression-Free Survival in Small Cell Bronchogenic
Carcinoma Patients
Progression-Free
Induction Intensification Survival (mo)
3 CR 3 CR 7, 13+, 20+
3 PR 2 CR, 1 PR 2+, 5+, 12+
1 surgically NED Still NED 9+
1 SD 1 CR 9+
2 relapse 2 CR 4+, 6
Abbreviations: CR, complete response; PR, partial response; NED, no evident
disease following surgery; SD, stable disease.
one with non-oat cell carcinoma) received intensification therapy. Their
progression-free survival has been 14, 6+, and 1+ months. Five patients who
had soft tissue sarcoma, squamous cell carcinoma of the lung, gastric
carcinoma, large cell lymphoma, and adenocarcinoma of the lung were treated
upon relapse; one died early, and progression-free survivals in the other four
lasted only 1,2,2, and 4 months.
Toxicity
Hematologic toxicity in these patients is shown in Tables 3 and 4. Time to
granulocyte recovery for 100, 500, and 1,000/mm 3
was identical for first and
second courses, the median number of days being 19,21, and 23, respectively,
from day 1 of chemotherapy. In the second course, time to platelet recovery to
50,000/mm 3
and 100,000/mm 3 was slower than in the first: 23 compared with
20 and 28 compared with 21 days, respectively. Among the 15 patients in the
Table 3. Days Until Neutrophil Recovery Following Start of High-Dose
CVP Regimen
First Course
Second Course
>100/mm 3 >500/mm 3 >1,000/mm3 >100/mm3 >500/mm3 >1,000/mm 3
19 (10-26) 3 21 (12-34) 23 (14-39) 19(14-52) 22(12-54) 23(12-56)
Abbreviation: CVP, cyclophosphamide, VP-16-213 (etoposide), platinum (cisplatin).
'Median and range.
Table 4. Days Until Platelet Recovery Following Start
of High-Dose CVP Regimen
First Course
Second Course
>50x1Q3/mm3 >100x1Q3/mm3 >50 x 10 3 /mm3 >100x1Q3/mm3
20 (15-32)» 22 (17-28) 24 (12-51) 28 (18-60)
Abbreviation: CVP, cyclophosphamide, VP-16-213 (etoposide), platinum (cisplatin).
'Median and range.